Feasibility study of direct fentanyl patch introduction without prior opioid titration

International Journal of Clinical Oncology

Volumn 14, Issue 3, 2009, Pages 202-207

  Matsui, Takanori ^a   Kojima, Taiki ^a   Kojima, Hiroshi ^a   Iwamoto, Naoko ^a   Kure, Shigehiro ^a   Uemura, Takanori ^a   Fujimitsu, Yasunobu ^a   Sakamoto, Junichi ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Direct introduction; Fentanyl patch (FP); Opioid induced bowel dysfunction (OBD); Prospective feasibility study

Indexed keywords

FENTANYL; OPIATE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CONSTIPATION; DIGESTIVE SYSTEM CANCER; DROWSINESS; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; NAUSEA; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; VOMITING; GASTROINTESTINAL TUMOR; INTRACTABLE PAIN; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADMINISTRATION, CUTANEOUS; AGED; ANALGESICS, OPIOID; FEASIBILITY STUDIES; FEMALE; FENTANYL; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PAIN, INTRACTABLE; PROSPECTIVE STUDIES;

EID: 70349566510     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0829-4     Document Type: Article

References (15)

1. World Health Organization (1986) Cancer pain relief. World Health Organization, Geneva
2. Jacox A, Carr DB, Payne R, et al. (1994) Clinical practice guideline no. 9. Agency for Health Care Policy and Research (AHCPR), Rockville, Publication no. 94-0593
3. World Health Organization(1996) Cancer pain relief, 2nd edn. World Health Organization, Geneva
4. G.W. Hanks F. Conno N. Cherny, et al. 2001 Morphine and alternative opioids in cancer pain: the EAPC recommendations Br J Cancer 84 587 593 11237376 10.1054/bjoc.2001.1680 1:CAS:528:DC%2BD3MXisVerur8%3D (Pubitemid 32238990)
5. American Society of Clinical Oncology (2001) Optimizing cancer care. The importance of symptom management; ASCO Curriculum. Kendall/Hunt Publishing Company, Dubuque
6. A. Kurz D.I. Sessler 2003 Opioid-induced bowel dysfunction; pathophysiology and potential new therapies Drugs 7 649 671 10.2165/00003495- 200363070-00003 (Pubitemid 36408072)
7. J. Thomas 2007 Opioid-induced bowel dysfunction J Pain Symptom Manage 1 103 113
8. M. Pappagallo 2001 Incidence, prevalence, and management of opioid bowel dysfunction Am J Surg 5A Suppl 11S 18S 10.1016/S0002-9610(01)00782-6
9. S. Ahmedzai D. Brooks 1997 Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life J Pain Symptom Manage 5 254 261 10.1016/S0885-3924(97)00082-1 (Pubitemid 27240678)
10. P.A. Sloan D.E. Moulin H. Hays 1998 A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain J Pain Symptom Manage 2 102 111 10.1016/S0885-3924(98)00044-X (Pubitemid 28400160)
11. L. Allan H. Hays N.H. Jensen, et al. 2001 Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain BMJ 7295 1154 1158 10.1136/bmj.322.7295.1154
12. A.J. Clark S.H. Ahmedzai L.G. Allan, et al. 2004 Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain Curr Med Res Opin 9 1419 1428 10.1185/ 030079904X2114 (Pubitemid 39361345)
13. K. Mystakidou E. Parpa E. Tsilika, et al. 2004 Pain management of cancer patients with transdermal fentanyl J Pain 5 119 132 15042520 10.1016/j.jpain.2003.12.003 1:CAS:528:DC%2BD2cXisVSmtrw%3D (Pubitemid 38850183)
14. M. Narita S. Imai S. Ozaki, et al. 2003 Reduced expression of a novel mu-opioid receptor (MOR) subtype MOR-1B in CXBK mice: implications of MOR-1B in the expression of MOR-mediated responses Eur J Neurosci 12 3193 3198 10.1111/j.1460-9568.2003.03052.x (Pubitemid 38031045)
15. L. Manara G. Bianchi P. Ferretti, et al. 1986 Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites J Pharmacol Exp Ther 3 945 949